Teva Medical to sell Ortec's wound treatment:
This article was originally published in Clinica
Teva Medical, a subsidiary of Israeli generic drug company company Teva Pharmaceutical Industries, is to promote and sell New York-based Ortec International's wound healing product OrCel in Israel. The deal is initially for 10 years, and includes a requirement for Teva to obtain regulatory approval and reimbursement of the tissue-engineered treatment for chronic wounds and other dermatological conditions in Israel. Teva is one of the world's largest generic pharmaceutical firms. OrCel is a collagenic sponge seeded with allogeneic epidermal and dermal cells.